LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Progression-Free Survival for WM | IMBRUVICA® (ibrutinib)
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Percentage Progression-free survival and overall survival on treatment.... | Download Scientific Diagram
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
REVEL Trial Progression-Free Survival for mNSCLC | CYRAMZA® (ramucirumab)
OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH.... EHA Library. Harrison C. Jun 9 2021; 324611
